^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TACC3 expression

i
Other names: TACC3, Transforming acidic coiled-coil containing protein 3, ERIC-1
Entrez ID:
Related biomarkers:
1m
Cellular senescence gene TACC3 associated with colorectal cancer risk via genetic and DNA methylated alteration. (PubMed, Arch Toxicol)
The regulatory effects of gene, variant, and DNA methylation were explored through dual-luciferase and 5-azacytidine treatment experiments, complemented by multiple database analyses...In addition, subjects with high-TACC3 expression presented an immunosuppressive microenvironment. These findings provide insights into the involvement of genetic variants of cellular senescence genes in the development and progression of colorectal cancer.
Journal • Epigenetic controller
|
TACC3 (Transforming acidic coiled-coil containing protein 3)
|
TACC3 expression
|
azacitidine
2ms
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. (PubMed, Cancer Res)
Finally, TACC3 inhibition in vivo elicited ICD in a vaccination assay and potentiated the anti-tumor efficacy of T-DM1 by inducing dendritic cell maturation and enhancing intratumoral infiltration of cytotoxic T cells. Together, these results illustrate that ICD is a key mechanism of action of T-DM1 that is lost in resistance and that targeting TACC3 can restore T-DM1-mediated ICD and overcome resistance.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • TACC3 (Transforming acidic coiled-coil containing protein 3) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
|
HER-2 positive • TACC3 expression
|
Kadcyla (ado-trastuzumab emtansine)
3ms
TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness. (PubMed, Cell Cycle)
A detailed understanding of the regulation of TACC3 expression, its key partners, and molecular functions in cancer cells is vital for uncovering the most vulnerable tumors and maximizing the therapeutic potential of targeting this highly oncogenic protein. In this review, we summarize the established and emerging interactors and spatiotemporal functions of TACC3 in cancer cells, discuss the potential of TACC3 as a biomarker in cancer, and therapeutic potential of its inhibition.
Review • Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR fusion • FGFR3 fusion • TACC3 expression
5ms
Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. (PubMed, Cell Death Dis)
Our studies further demonstrated that high expression of TACC3 and KIF11 mediated the resistance of PDAC to gemcitabine, and deficiency of TACC3 or KIF11 increased the sensitivity of PDAC cells to chemotherapy. In conclusion, our study reveals the fundamental role of TACC3 expression in PDAC cell proliferation and chemoresistance, suggesting that TACC3 can be used as a molecular marker to evaluate the prognosis of PDAC.
Journal • Tumor cell
|
TACC3 (Transforming acidic coiled-coil containing protein 3) • KIF11 (Kinesin Family Member 11)
|
TACC3 expression
|
gemcitabine
7ms
Family with sequence similarity 111 member B contributes to tumor growth and metastasis by mediating cell proliferation, invasion, and EMT via transforming acidic coiled-coil protein 3/PI3K/AKT signaling pathway in hepatocellular carcinoma. (PubMed, Environ Toxicol)
In vivo, FAM111B inhibition hampered tumor growth and metastasis of HCC. This study highlighted a key player of FAM111B in modulating the malignant biological progression of HCC via TACC3/PI3K/AKT signaling pathway, displaying a potential therapeutic target for HCC.
Journal
|
TACC3 (Transforming acidic coiled-coil containing protein 3)
|
TACC3 expression
12ms
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. (PubMed, Cell Death Differ)
Targeting TACC3 by guide RNAs or small molecule inhibitors strongly inhibits growth of organoids and breast cancer cell line- and patient-derived xenografts with CA by induction of multipolar spindles, mitotic and G1 arrest. Altogether, our results show that TACC3 is a multifunctional driver of highly aggressive breast tumors with CA and that targeting TACC3 is a promising approach to tackle this disease.
Journal
|
TACC3 (Transforming acidic coiled-coil containing protein 3) • HDAC2 (Histone deacetylase 2) • FOXM1 (Forkhead Box M1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KIFC1 (Kinesin Family Member C1) • APAF1 (Apoptotic peptidase activating factor 1)
|
TACC3 expression
1year
Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification (AACR 2023)
Notably, we demonstrated that high CA tumors express much higher levels of TACC3, and high TACC3 expression leads to drastically worse clinical outcome in cancer patients with CA. Altogether, our results show, for the first time, that TACC3 is a multifunctional driver of the growth of the highly aggressive breast tumors with CA and that targeting TACC3 is a promising approach to tackle this aggressive disease.
IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • TACC3 (Transforming acidic coiled-coil containing protein 3) • HDAC2 (Histone deacetylase 2) • PLK4 (Polo Like Kinase 4) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KIFC1 (Kinesin Family Member C1) • APAF1 (Apoptotic peptidase activating factor 1)
|
TACC3 expression
over1year
Tumor-augmenting Effect of Histone Methyltransferase WHSC1 on Colorectal Cancer Via Epigenetic Upregulation of TACC3 and PI3K/Akt Activation. (PubMed, Arch Med Res)
The results of this study revealed TACC3 as a target of WHSC1 in CRC that is positively correlated with PI3K/Akt pathway activation and tumor development.
Journal • Epigenetic controller
|
TACC3 (Transforming acidic coiled-coil containing protein 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
TACC3 expression
over1year
Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification (SABCS 2022)
Notably, we demonstrated that high CA tumors express much higher levels of TACC3, and high TACC3 expression, in association with its downstream effectors, KIFC1, HDAC2 and MBD2, leads to drastically worse clinical outcome in cancer patients with CA. Altogether, our results show, for the first time, that TACC3 is a multifunctional driver of the growth of the highly aggressive breast tumors with CA and that targeting TACC3 is a promising approach to tackle this aggressive disease.
IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • TACC3 (Transforming acidic coiled-coil containing protein 3) • HDAC2 (Histone deacetylase 2) • PLK4 (Polo Like Kinase 4) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KIFC1 (Kinesin Family Member C1) • APAF1 (Apoptotic peptidase activating factor 1)
|
TACC3 expression
over1year
Elevated expression of transforming acidic coiled-coil-containing protein 3 (TACC3) reflects aggressiveness of primary central nervous system lymphomas. (PubMed, Pathol Int)
Disease-free survival and overall survival of patients with high TACC3 expression were significantly shorter (p < 0.01 and p < 0.05, respectively). These results suggest that elevated expression of TACC3 could reflects aggressiveness of primary central nervous system lymphomas.
Journal
|
TP53 (Tumor protein P53) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
TACC3 expression • TP53 expression
over1year
The prognostic activity of transforming acidic coiled-coil 3 (TACC3) immunohistochemical expression in colon adenocarcinoma patients. (PubMed, Prz Gastroenterol)
A multivariate analysis demonstrated that the grade of tumour differentiation (HR = 2.740; 95% CI: 1.864-4.027, p < 0.001) and TACC3 immunoexpression in healthy tissues (HR = 1.700; 95% CI: 1.073-2.694) were independent risk factors for worse survival of patients. The high level of TACC3 immunoexpression in cancerous tissue was not associated with malignancy-related clinicopathological factors and 5-year overall survival of patients.
Journal
|
TACC3 (Transforming acidic coiled-coil containing protein 3)
|
TACC3 expression
over1year
Abnormal TACC3 Expression is an Independent Prognostic Biomarker in Lung Carcinoma. (PubMed, Front Biosci (Landmark Ed))
The present study provides evidence that TACC3 expression is upregulated in LUAD and may be an independent risk factor for worse prognosis in these patients.
Journal
|
TACC3 (Transforming acidic coiled-coil containing protein 3)
|
TACC3 expression
over1year
High Expression of TACC3 Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients. (PubMed, Dis Markers)
The findings from this research offer robust proof that the expression of TACC3 could be a prognostic marker correlated with TIICs in LUAD. TACC3 can also provide new ideas for immunotherapy as a potential therapeutic target.
Journal • IO biomarker
|
TACC3 (Transforming acidic coiled-coil containing protein 3)
|
TACC3 expression
almost3years
TACC3 Promotes Gastric Carcinogenesis by Promoting Epithelial-mesenchymal Transition Through the ERK/Akt/cyclin D1 Signaling Pathway. (PubMed, Anticancer Res)
TACC3 contributes to gastric tumorigenesis by promoting EMT via the ERK/Akt/cyclin D1 signaling pathway. The correlation between TACC3 expression and multiple clinicopathological variables implies that its effective therapeutic targeting in GC will depend on the tumor subtype.
Journal
|
CCND1 (Cyclin D1) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
CCND1 expression • TACC3 expression
almost3years
Transforming acidic coiled-coil protein-3: a novel marker for differential diagnosis and prognosis prediction in endocervical adenocarcinoma. (PubMed, Mol Med)
Taken together, our findings identify that TACC3 is a promising complementary biomarker for diagnosis and prognosis for patients with ECA.
Journal
|
TACC3 (Transforming acidic coiled-coil containing protein 3) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
TACC3 expression • MSH6 expression
almost3years
Inhibiting of TACC3 Promotes Cell Proliferation, Cell Invasion and the EMT Pathway in Breast Cancer. (PubMed, Front Genet)
Moreover, TACC3 knockdown suppressed the expression of E-cadherin, but increased the expression of N-cadherin, Snail, ZEB1, and TWIST, which indicate that TACC3 may impact the migration of breast cancer cells in vitro. Taken together, these findings indicate that TACC3 may serve as a prognostic and therapeutic indicator of breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CDH1 (Cadherin 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
TACC3 expression • CDH1 expression • ZEB1 expression